SCHEMBL875439

SCHEMBL875439

OCCC[C@@H](O)Cc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 4/20 0.44
TDP1 Q9NUW8 1/20 0.43
CYP1A2 P05177 1/20 0.42
EPHX1 P07099 1/20 0.41
CSNK1E P49674 1/20 0.41
TSHR P16473 1/20 0.41
FOLH1 Q04609 1/20 0.41
CCR3 P51677 1/20 0.41
SRR Q9GZT4 1/20 0.40
SLC1A3 P43003 1/20 0.40
SLC1A2 P43004 1/20 0.40
SLC1A1 P43005 1/20 0.40
ALPI P09923 1/20 0.39
PKM P14618 1/20 0.39
PTGS1 P23219 1/20 0.39
XIAP P98170 1/20 0.39
SLC7A5 Q01650 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4964246 1.00 TRPA1 (0.44) TRPA1TDP1CYP1A2EPHX1CSNK1E
SCHEMBL4964239 1.00 TRPA1 (0.44) TRPA1TDP1CYP1A2EPHX1CSNK1E
SCHEMBL1598160 0.94 CSNK1E (0.44) TRPA1TDP1CYP1A2EPHX1CSNK1E
SCHEMBL11297877 0.92 CSNK1E (0.46) TRPA1TDP1CYP1A2EPHX1CSNK1E
SCHEMBL27622402 0.92 CSNK1E (0.46) TRPA1TDP1CYP1A2EPHX1CSNK1E
SCHEMBL27890776 0.92 CSNK1E (0.46) TRPA1TDP1CYP1A2EPHX1CSNK1E
SCHEMBL17075353 0.92 CSNK1E (0.46) TRPA1TDP1CYP1A2EPHX1CSNK1E
SCHEMBL5097040 0.89 TRPA1 (0.48) TRPA1CYP1A2EPHX1CSNK1EFOLH1
SCHEMBL8425091 0.87 TRPA1 (0.47) TRPA1TDP1CYP1A2EPHX1TSHR
SCHEMBL5868422 0.87 TRPA1 (0.47) TRPA1TDP1CYP1A2EPHX1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9359306-B2 Process for preparing pan-CDK inhibitors of the formula (I), and intermediates in the preparation BAYER INTELLECTUAL PROPERTY GMBH (DE) 2016-06-07 US disclosed
US-20130245261-A1 PROCESS FOR PREPARING PAN-CDK INHIBITORS OF THE FORMULA (I), AND INTERMEDIATES IN THE PREPARATION BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-09-19 US disclosed
EP-2619186-A1 PROCESS FOR PREPARING PAN-CDK INHIBITORS OF THE FORMULA (I), AND INTERMEDIATES IN THE PREPARATION Bayer Pharma Aktiengesellschaft (DE) 2013-07-31 EP disclosed
WO-2012038411-A1 PROCESS FOR PREPARING PAN-CDK INHIBITORS OF THE FORMULA (I), AND INTERMEDIATES IN THE PREPARATION BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-03-29 WO disclosed
US-7230135-B2 Synthesis of P-chiral bisphospholane ligands and their transition metal complexes for use as asymmetric hydrogenation catalysts WARNER LAMBERT COMPANY LLC (US) 2007-06-12 US disclosed
US-7230135-B2 Synthesis of P-chiral bisphospholane ligands and their transition metal complexes for use as asymmetric hydrogenation catalysts WARNER LAMBERT COMPANY LLC (US) 2007-06-12 US disclosed
US-7230135-B2 Synthesis of P-chiral bisphospholane ligands and their transition metal complexes for use as asymmetric hydrogenation catalysts WARNER LAMBERT COMPANY LLC (US) 2007-06-12 US disclosed
EP-1341799-B1 P-CHIRALE BISPHOSPHOLANE LIGANDS, THEIR TRANSITION METAL COMPLEXES WARNER LAMBERT CO (US) 2005-03-16 EP disclosed
US-20040215027-A1 Synthesis of P-chiral bisphospholane ligands and their transition metal complexes for use as asymmetric hydrogenation catalysts HOGE GARRETT STEWART 2004-10-28 US disclosed
US-6750171-B2 IMPROVE ENANTIOSELECTIVITY IN ASYMMETRIC REACTIONS WARNER-LAMBERT COMPANY LLC 2004-06-15 US disclosed
US-20030236433-A1 Synthesis of P-chiral bisphospholane ligands and their transition metal complexes for use as asymmetric hydrogenation catalysts HOGE GARRETT STEWART (US) 2003-12-25 US disclosed
EP-1341799-A1 P-CHIRALE BISPHOSPHOLANE LIGANDS, THEIR TRANSITION METAL COMPLEXES Warner-Lambert Company LLC (US) 2003-09-10 EP disclosed
US-6605745-B2 Locates chirality closer to the metal center than known metal phospholane complexes; provide high enantiomeric excesses of formed compounds HOGE II GARRETT STEWART (US) 2003-08-12 US disclosed
US-20020087017-A1 Synthesis of P-chiral bisphospholane ligands and their transition metal complexes for use as asymmetric hydrogenation catalysts HOGE GARRETT STEWART (US) 2002-07-04 US disclosed
WO-2002048161-A1 P-CHIRALE BISPHOSPHOLANE LIGANDS, THEIR TRANSITION METAL COMPLEXES WARNER-LAMBERT COMPANY LLC (US) 2002-06-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040215027-A1 Synthesis of P-chiral bisphospholane ligands and their transition metal complexes for use as asymmetric hydrogenation catalysts PHOSPHO1, BPGM, PHPT1 TRPA1 3613/4885TDP1 4683/4885CYP1A2 2096/4885
US-20130245261-A1 PROCESS FOR PREPARING PAN-CDK INHIBITORS OF THE FORMULA (I), AND INTERMEDIATES IN THE PREPARATION CDK1, CDK9, CDK6 TRPA1 4882/4885TDP1 729/4885CYP1A2 1630/4885
US-20030236433-A1 Synthesis of P-chiral bisphospholane ligands and their transition metal complexes for use as asymmetric hydrogenation catalysts PHOSPHO1, BPGM, PHPT1 TRPA1 3613/4885TDP1 4683/4885CYP1A2 2096/4885
US-20020087017-A1 Synthesis of P-chiral bisphospholane ligands and their transition metal complexes for use as asymmetric hydrogenation catalysts PHOSPHO1, BPGM, PHPT1 TRPA1 3613/4885TDP1 4683/4885CYP1A2 2096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.